84200-07-7

Upstream product

• 100-43-6 4-vinylpyridine 
• 201230-82-2 carbon monoxide 

Downstream Products

• 84200-06-6 3-(pyridin-4-yl)propanenitrile 
• 30532-36-6 3-(pyridin-4-yl)propan-1-amine 
• 13258-63-4 4-(2-Aminoethyl)pyridine 
• 101938-75-4 N-(2-[4]pyridyl-ethyl)-toluene-4-sulfonamide 
• 107774-78-7 N-(2-[4]pyridyl-ethyl)-benzamide 

Relevant academic research and scientific papers

Combination of transition metal Rh-catalysis and tautomeric catalysis through a bi-functional ligand for one-pot tandem methoxycarbonylation-aminolysis of olefins towards primary amides

Combination of transition metal catalysis with organocatalysis in ways of synergetic catalysis, cooperative catalysis, or/and sequential catalysis has been emerged as a powerful strategy to promote organic transformations that cannot be achieved by each individual independently. Herein, a new protocol for the synthesis of primary amides from olefins, CO and NH3 through one-pot tandem methoxycarbonylation-aminolys was presented over a bi-functional ligand (L1) based rhodium catalyst with functions of co-catalysis. L1 is composed of the phosphino-fragment and the amino-/imino- tautomeric moiety. Then L1-based Rh-catalytic system demonstrated a combination of Rh-P transition metal catalysis and the tautomeric catalysis. In this tandem methoxycarbonylation-aminolysis, NH3 also served as a ligand to work together with the phosphino-fragment to synergetically modify the performance of Rh-catalyst responsible for the first-step methoxycarbonylation of olefin to generate the esters, and the Rh-tailed tautomeric catalyst was in charge of the subsequent aminolysis to generate the targeted primary amides.

Cyclopropylpropenamides

The invention relates to compounds of the formula STR1 Y is O or S, *A is paraphenylene or *--(CH2)n --(X)m --(CH2)r --, X is O, S or --CH=CH--, n or r, independently, are integers from 0 to 3, s is an integer from 0 to 1, m is an integer from 0 to 1, provided that when m is 1, n+s must be at least 2, R1 and R2, independently, are hydrogen, lower alkyl, cycloalkyl, lower alkenyl, Het or aryl, *E is STR2 or --(CH2)k -- wherein k is an integer from 0 to 4, R3, R4 and R8 are independently hydrogen or lower alkyl, R5 and R6, independently are hydrogen or lower alkyl, R7 is hydrogen, lower alkyl, cycloalkyl, Het-lower alkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen, oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and their enantiomers, diastereomers and racemic mixtures thereof, as well as when *E is STR3 their geometric isomers, and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I exhibit activity as platelet activating factor (PAF) antagonists and are, therefore, useful in disease states characterized by excess platelet activating factor or for the prevention and treatment of cardiovascular diseases, pulmonary diseases, immunological disorders, inflammatory diseases, dermatological disorders, shock or transplant rejection.